April 07, 2015
Boehringer Ingelheim Pharmaceuticals Inc. asked the D.C. Circuit on Monday for another shot at defending a lower court order that largely rejected the Federal Trade Commission's documents request in its investigation into an alleged Aggrenox pay-for-delay deal, arguing the circuit court's ruling slashed work product protections.
September 12, 2013
The Federal Trade Commission told the D.C. Circuit on Wednesday that it should force Boehringer Ingelheim Pharmaceuticals Inc. to turn over documents about a $100 million drug co-promotion deal with Barr Pharmaceuticals Inc., saying the information could indicate an unlawful pay-for-delay agreement.